Daily Stock Analysis, APRI, Apricus Biosciences Inc, priceseries

Apricus Biosciences Inc. Daily Stock Analysis
Stock Information
Open
0.23
Close
0.22
High
0.23
Low
0.21
Previous Close
2.59
Daily Price Gain
-2.37
YTD High
8.40
YTD High Date
Jan 15, 2019
YTD Low
0.21
YTD Low Date
Jan 23, 2019
YTD Price Change
-7.03
YTD Gain
-96.97%
52 Week High
17.40
52 Week High Date
Jun 12, 2018
52 Week Low
0.21
52 Week Low Date
Jan 23, 2019
52 Week Price Change
-11.73
52 Week Gain
-98.16%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 17. 2017
45.30
Feb 28. 2017
89.64
29 Trading Days
97.89%
Link
LONG
Jul 10. 2017
35.70
Jul 11. 2017
38.40
1 Trading Days
7.56%
Link
LONG
Aug 16. 2017
40.80
Aug 28. 2017
44.67
8 Trading Days
9.49%
Link
LONG
Sep 5. 2017
46.80
Sep 20. 2017
51.73
11 Trading Days
10.53%
Link
LONG
Dec 15. 2017
52.20
Jan 24. 2018
73.24
25 Trading Days
40.30%
Link
LONG
Sep 11. 2018
9.90
Sep 12. 2018
10.50
1 Trading Days
6.06%
Link
LONG
Mar 7. 2019
3.04
Mar 13. 2019
3.24
4 Trading Days
6.66%
Link
Company Information
Stock Symbol
APRI
Exchange
NasdaqCM
Company URL
http://www.apricusbio.com
Company Phone
(858) 222-8041
CEO
Richard W. Pascoe
Headquarters
California
Business Address
11975 EL CAMINO REAL,, SUITE 300, SAN DIEGO,, CA 92130
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Other
CIK
0001017491
About

Apricus Biosciences, Inc. is a pharmaceutical company focus on the development and commercialization of products and product candidates in the areas of specialty urology and rheumatology. The company products include Vitaros and Femprox. It operates through Pharmaceutical segment which designs, and develops pharmaceutical products including those with its NexACT platform. Apricus Biosciences was founded in 1987 and is headquartered in San Diego, CA.

Description

Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development and commercialization of product candidates in the areas of urology and rheumatology. Its lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. The company also engages in developing RayVa, which is in Phase 2 development for the treatment of Raynaud's Phenomenon associated with scleroderma; and Fispemifene, a tissue-specific selective estrogen receptor modulator for the treatment of secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. It operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.